Cargando…
Polyclonal free light chains: a biomarker of inflammatory disease or treatment target?
Free light chains are proteins produced by B lymphocytes during the process of antibody synthesis. Their production, as a reflection of B cell activation, can give insight into the activity of the adaptive immune system. In recent years, an automated immunoassay that provides quantitative measuremen...
Autores principales: | Brebner, Judith A., Stockley, Robert A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Faculty of 1000 Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564472/ https://www.ncbi.nlm.nih.gov/pubmed/23413370 http://dx.doi.org/10.3410/M5-4 |
Ejemplares similares
-
Polyclonal light chains in cerebrovascular disease
por: Fiori, Patrizia, et al.
Publicado: (2010) -
Free light chains: potential biomarker and predictor of mortality in alpha-1-antitrypsin deficiency and usual COPD
por: Hampson, Judith A., et al.
Publicado: (2016) -
Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies
por: Kumar, Shaji, et al.
Publicado: (2019) -
Elevated serum polyclonal immunoglobulin free light chains in patients with severe asthma
por: Basile, Umberto, et al.
Publicado: (2023) -
The Association between Polyclonal Combined Serum Free Light Chain Concentration and Mortality in Individuals with Early Chronic Kidney Disease
por: Assi, Lakhvir K., et al.
Publicado: (2015)